← All Abbvie INC filings

Abbvie INC Schedule 13G passive stakes

Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.

NYSE
ABBV
Abbvie INC
SCHEDULE: Vanguard Reports Zero AbbVie Stake Post-Realignment
The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AbbVie Inc. following an internal corporate realignment.
NYSE
ABBV
Abbvie INC
SCHEDULE: Vanguard Group Discloses 10.03% Passive Stake in AbbVie Inc.
The Vanguard Group has filed an amended Schedule 13G, reporting a 10.03% beneficial ownership stake in AbbVie Inc. as of June 30, 2025.
NYSE
ABBV
Abbvie INC
SCHEDULE 13G: AbbVie Discloses 9.0% Stake in Xilio Therapeutics, Signaling Strategic Investment
AbbVie Inc. has disclosed a significant 9.0% beneficial ownership stake in Xilio Therapeutics, Inc., acquiring over 4.3 million shares of common stock.